Safety of Sublingual dmLT for ETEC
- Conditions
- Gastroenteritis Escherichia Coli
- Interventions
- Biological: Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine
- First Posted Date
- 2014-02-03
- Last Posted Date
- 2019-01-28
- Target Recruit Count
- 80
- Registration Number
- NCT02052934
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center - Gastroenterology, Hepatology and Nutrition, Cincinnati, Ohio, United States
Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Biological: Placebo VaccineBiological: RSV LID ΔM2-2 Vaccine
- First Posted Date
- 2014-01-20
- Last Posted Date
- 2016-12-21
- Target Recruit Count
- 3
- Registration Number
- NCT02040831
- Locations
- 🇺🇸
Center for Immunization Research, JHU, Baltimore, Maryland, United States
A Phase 1, Open Label, Ascending Dose Cohort Study of the Pharmacokinetics of Anti-Influenza Hyperimmune Intravenous Immunoglobulin in Healthy Subjects
- Conditions
- FluInfluenza
BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance
- Conditions
- Kidney Transplantation
- Interventions
- Biological: anti-thymocyte globulinRadiation: Total Body IrradiationBiological: bone marrow transplant
- First Posted Date
- 2014-01-08
- Last Posted Date
- 2018-09-24
- Target Recruit Count
- 4
- Registration Number
- NCT02029638
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral Therapy
- First Posted Date
- 2014-01-07
- Last Posted Date
- 2021-11-05
- Target Recruit Count
- 8
- Registration Number
- NCT02028403
- Locations
- 🇺🇸
Washington University Therapeutics (WT) CRS, Saint Louis, Missouri, United States
🇺🇸University of Colorado Hospital CRS, Aurora, Colorado, United States
🇺🇸Vanderbilt Therapeutics (VT) CRS, Nashville, Tennessee, United States
Evaluating the Safety and Effectiveness of a Dengue Virus Vaccine in Healthy Adults
- Conditions
- Dengue
- Interventions
- Biological: rDEN2∆30-7169Biological: TetraVax-DV-TV003Biological: Placebo
- First Posted Date
- 2013-12-27
- Last Posted Date
- 2015-12-15
- Target Recruit Count
- 48
- Registration Number
- NCT02021968
- Locations
- 🇺🇸
University of Vermont Vaccine Testing Center, Burlington, Vermont, United States
🇺🇸Center for Immunization Research (CIR), Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
- Conditions
- T-LymphocytopeniaIdiopathic CD4-Positive
- Interventions
- First Posted Date
- 2013-12-19
- Last Posted Date
- 2025-05-28
- Target Recruit Count
- 40
- Registration Number
- NCT02015013
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Study of Controlled Human Malaria Infections to Evaluate Protection After Intravenous or Intramuscular Administration of PfSPZ Vaccine in Malaria-Naive Adults
- Conditions
- Malaria
- Interventions
- Biological: PfSPZ Vaccine
- First Posted Date
- 2013-12-19
- Last Posted Date
- 2019-12-17
- Target Recruit Count
- 141
- Registration Number
- NCT02015091
- Locations
- 🇺🇸
University of Maryland Center for Vaccine Dev, Baltimore, Baltimore, Maryland, United States
🇺🇸National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Anti-Influenza Hyperimmune Intravenous Immunoglobulin Pilot Study (INSIGHT 005: Flu-IVIG Pilot)
- Conditions
- Influenza
- Interventions
- Biological: PlaceboBiological: Intravenous hyperimmune immunoglobulin (Flu-IVIG)
- First Posted Date
- 2013-12-11
- Last Posted Date
- 2016-08-15
- Target Recruit Count
- 31
- Registration Number
- NCT02008578
- Locations
- 🇺🇸
Ohio State University Wexner Medical Center, Columbus, Ohio, United States
🇺🇸Miami Valley Hospital, Dayton, Ohio, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris
- Conditions
- Psoriasis
- Interventions
- Biological: UstekinumabBiological: AbataceptDrug: ABA PlaceboDrug: UST Placebo
- First Posted Date
- 2013-12-03
- Last Posted Date
- 2019-01-15
- Target Recruit Count
- 108
- Registration Number
- NCT01999868
- Locations
- 🇺🇸
Dermatology Research Associates, Los Angeles, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Tulane University School of Medicine: Dept. of Dermatology, New Orleans, Louisiana, United States